Pervasis secures $17M in third round of funding

09/17/2009 | Boston Globe (tiered subscription model), The

Pervasis Therapeutics has raised $17 million in financing from Flagship Venture Partners and other investors. The company will use the money to fund the advancement of ongoing drug-development efforts, including PVS-10200, a biotech drug used for restoring normal vasculature following interventions for peripheral arterial disease and other conditions.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Marlborough, MA
Test Technician
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT